Literature DB >> 11129071

Sensitive and specific high-performance liquid chromatographic assay for 4'-hydroxyflurbiprofen and flurbiprofen in human urine and plasma.

J M Hutzler1, R F Frye, T S Tracy.   

Abstract

A high-performance liquid chromatographic assay has been developed for the simultaneous quantitation of flurbiprofen and its major metabolite, 4'-hydroxyflurbiprofen, in urine and plasma. No extraction procedure was necessary for analysis of these compounds, which reduced time involved in sample preparation. The analytes were separated on a Brownlee Spheri-5 C18 column with a mobile phase of acetonitrile-20 mM dibasic potassium phosphate pH 3 buffer (40:60, v/v). Fluorescence detection was utilized with an excitation wavelength of 260 nm and an emission wavelength of 320 nm, providing excellent sensitivity. The limit of quantitation for 4'-hydroxyflurbiprofen and flurbiprofen was 0.25 microg/ml in urine and 0.05 microg/ml and 0.25 microg/ml, respectively, in plasma. All components were eluted within 16 min. Intra-day, inter-day, freeze-thaw, and in process stability were tested for both compounds and the coefficient of variation was less than 14% in all cases. This method provides a sensitive and specific assay for the detection of flurbiprofen and 4'-hydoxyflurbiprofen in urine and plasma and is suitable for use in in vivo studies evaluating the regulation of CYP2C9 activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129071     DOI: 10.1016/s0378-4347(00)00393-5

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  5 in total

1.  Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.

Authors:  Craig R Lee; John A Pieper; Reginald F Frye; Alan L Hinderliter; Joyce A Blaisdell; Joyce A Goldstein
Journal:  Eur J Clin Pharmacol       Date:  2003-02-26       Impact factor: 2.953

2.  Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.

Authors:  N K Zgheib; R F Frye; T S Tracy; M Romkes; R A Branch
Journal:  Br J Clin Pharmacol       Date:  2006-10-19       Impact factor: 4.335

3.  Differential genotype dependent inhibition of CYP2C9 in humans.

Authors:  Vikas Kumar; Richard C Brundage; William S Oetting; Ilo E Leppik; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2008-03-31       Impact factor: 3.922

4.  Clinical study on the bioequivalence of two tablet formulations of flurbiprofen.

Authors:  Latif Ozbay; Durisehvar Ozer Unal; Iclal Cakici; Aysen Fenercioglu; Dilek Erol
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jan-Mar       Impact factor: 2.441

5.  Functional evolution of the vitamin D and pregnane X receptors.

Authors:  Erica J Reschly; Afonso Celso Dias Bainy; Jaco Joaquim Mattos; Lee R Hagey; Nathan Bahary; Sripal R Mada; Junhai Ou; Raman Venkataramanan; Matthew D Krasowski
Journal:  BMC Evol Biol       Date:  2007-11-12       Impact factor: 3.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.